Document:

xene-ex101_12.htm

 

Exhibit 10.1

August 6, 2021

Genentech, Inc. 

1 DNA Way

South San Francisco, CA 94080

USA

Attention: Pharma Partnering, Alliance Management

	
Re: 
	
Collaborative Research and License Agreement between Xenon Pharmaceuticals Inc. (“Xenon”), on the one hand, and Genentech, Inc. (“GNE”) and F. Hoffmann-La Roche Ltd (“Roche” and, together with GNE, “Genentech”), made as of December 22, 2011 (as amended to date, the “Agreement”)

Dear Sir/Madam:

Pursuant to Section 12.3(a)(ii) of the Agreement, Xenon and Genentech hereby agree to terminate the Agreement in accordance this letter agreement. The capitalized terms used but not defined in this letter agreement have the meanings ascribed to them in the Agreement.

	
1.
	
TERMINATION EFFECTIVE DATE

The termination of the Agreement shall take effect on August 6, 2021 (“Termination Date”). 

	
2.
	
CEASED DEVELOPMENT

Genentech hereby represents and warrants to Xenon that, as of the date hereof, Genentech has Ceased Development of all SMC Licensed Products in the Territory containing Collaboration Compounds or containing other Compounds to which Xenon is eligible for Milestone Payments and/or Royalties under the Agreement. 

	
3.
	
POST-TERMINATION LICENSES

	
3.1
	
Notwithstanding anything to the contrary in the Agreement or in this letter agreement, Genentech will retain a non-exclusive, perpetual, irrevocable, royalty-free, fully paid-up, non-transferable, non-sublicensable (other than to Genentech’s Affiliates) license under the Licensed IP to research and Develop SMC Licensed Products (but excluding the right to sell any SMC Licensed Products). 

	
3.2
	
Genentech hereby grants to Xenon a non-exclusive, perpetual, irrevocable, royalty-free, fully paid-up, non-transferable, non-sublicensable (other than to Xenon’s Affiliates) license under the Genentech IP (including all study data, results and regulatory filings relating to same that are in the possession of Xenon as of the date hereof) utilized by Genentech in the research and Development of all SMCs and SMC Licensed Products respecting which such SMC is Covered by a Patent Right within the Licensed IP within the Territory solely for the purposes of conducting research within Xenon with respect to such SMCs and SMC Licensed Products (for clarity, excluding for any Development or Commercialization purposes).

 

 

 

	
3.3
	
Either Party may enter into subcontracts with Third Parties and Affiliates acting by or for such Party with respect to the activities authorized under this Section 3; provided, that in each instance such contract is consistent with the terms and conditions of this letter agreement. 

	
3.4
	
Following the Termination Date, Genentech will provide a presentation on the topic of biology of Nav1.7, subject to the Parties’ mutual agreement as to the scope and timing of such presentation. The content of such presentation shall be considered Genentech IP and subject to the license set forth in Section 3.2, provided however that any Confidential Information of Genentech included therein shall be deemed Confidential Information of Genentech provided to Xenon under the Agreement and, notwithstanding anything to the contrary in Section 4.1(c) of this letter agreement, shall remain the Confidential Information of Genentech for a period of ten (10) years following the Termination Date.

	
4.
	
SURVIVING OBLIGATIONS

	
4.1
	
Notwithstanding anything to the contrary in the Agreement, the termination of the Agreement shall not affect the rights and obligations of the Parties, which, from the context of the Agreement, are intended to survive termination or expiration of the Agreement, including:

	
 
	
(a)
	
Sections 9.3, 9.5, and Articles 10, 12, 13, 14, 15 and 16 (except 16.1(f)(ii)); and 

	
 
	
(b)
	
Article 1, with the following modification:

	
 
	
(i)
	
the definition of “Post Research Term IP” is hereby amended to exclude any Intellectual Property generated by Xenon following the Termination Date; and

	
 
	
(c)
	
Article 11, with the following modifications:

	
 
	
(i)
	
notwithstanding anything to the contrary in the Agreement, either Party may make any Disclosure under Section 11.4 without the consent of the other Party with respect to any Collaboration Compound; and

	
 
	
(ii)
	
any Confidential Information disclosed during the term of the Agreement will remain the Confidential Information of the disclosing Party for a period of two (2) years following the Termination Date, except for any Xenon Research Data disclosed to Genentech pursuant to Amendment #4 to the Agreement, which shall remain the Confidential Information of Xenon for a period of ten (10) years following the Termination Date; and

	
 
	
(d)
	
Amendment #4 to the Agreement; and

	
 
	
(e)
	
Amended and Restated Amendment #7 to the Agreement (except for Sections 5.2(a) and 6 thereof as provided in Section 8.4 thereof).

	
4.2
	
Notwithstanding anything to the contrary in the Agreement, the rights and obligations of the Parties set forth in Sections 4.4 and 6.3(b) shall terminate as of the Termination Date. 

 

 

	
5.
	
INTELLECTUAL PROPERTY

Notwithstanding the generality of Section 4.1 of this letter agreement, Article 10 of the Agreement shall continue to apply following the Termination Date. For clarity, following the Termination Date, Genentech will continue to be primarily responsible for Prosecution of Patent Rights within Other Collaboration IP and Xenon Background IP in accordance with Section 10.4(a) of the Agreement and the process set forth in Sections 10.4(b) and 10.6 of the Agreement will continue to apply with respect to any patent abandonment by Genentech and patent enforcement, respectively.

	
6.
	
TRANSFER OF CERTAIN MATERIALS

	
6.1
	
Within sixty (60) days of the Termination Date, Genentech shall make available to Xenon or Xenon’s designee two straws of sperm of the IEM Model (“Sperm”). 

	
6.2
	
Xenon will have a one-time right, within three (3) months from the Termination Date, to inquire about the inventory of any Collaboration Compounds that Xenon would be interested to receive from Genentech. Genentech shall have sole discretion to decide whether to make such Collaboration Compounds(together with Sperm, the “Materials”) available to Xenon.

	
6.3
	
The following terms will apply to any transfer of any of the Materials:

	
 
	
(a)
	
All shipments will be EXW (Incoterms 2020). Notwithstanding anything to the contrary, Xenon will pick up the Materials from the applicable Genentech’s facility and Xenon will be responsible for export clearance.

	
 
	
(b)
	
Notwithstanding anything to the contrary in Section 6.2(a), Xenon shall be responsible for all costs and expenses associated with such shipments, including those involving export clearance, and promptly reimburse Genentech its direct out-of-pocket costs incurred in connection therewith.

	
 
	
(c)
	
The Materials will be solely used in accordance with the license granted to Xenon in Section 3.2 above. 

	
 
	
(d)
	
Xenon hereby represents and warrants that the Materials will not be used in humans or for diagnostic purposes involving humans, or in contact with any cells or other materials to be infused into humans.

	
 
	
(e)
	
Xenon will only use the Materials under suitable containment conditions and in compliance with all applicable federal, state, provincial and local statutes, regulations and guidelines.

	
6.4
	
Within forty-five (45) days of the Termination Date, Genentech will provide list of all Patent Rights within the Genentech IP as determined in good faith by Genentech.

	
6.5
	
Genentech makes no representation that the use of the Materials or any other Genentech IP will not infringe any patent or other proprietary right. Xenon will indemnify and hold Genentech and its directors, officers, agents and employees harmless from and against any claims or liabilities, which might arise as a result of Xenon’s use or possession of the Materials or Genentech IP.

 

 

	
6.6
	
ALL GENENTECH IP, INCLUDING WITHOUT LIMITATION THE MATERIALS, IS EXPERIMENTAL IN NATURE AND PROVIDED TO XENON WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR IMPLIED. GENENTECH SHALL NOT BE LIABLE FOR ANY USE OF ANY GENENTECH IP, INCLUDING WITHOUT LIMITATION THE MATERIALS, BY XENON, OR FOR ANY LOSS, CLAIM, DAMAGE, OR LIABILITY OF ANY KIND, THAT MAY ARISE FROM OR IN CONNECTION WITH THIS LETTER AGREEMENT OR FROM THE USE OR POSSESSION OF THE MATERIALS. 

	
7.
	
GENERAL

	
7.1
	
In the event of any conflict between the terms of this letter agreement and the terms of the Agreement, the terms of this letter agreement shall prevail. 

	
7.2
	
This letter agreement may be executed in two (2) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. Further, the execution of this letter agreement by exchanging electronic signatures (including, for clarity, via DocuSign) shall have the same legal force and effect as exchanging original signatures.

 

 

By the signatures below, the Parties have caused this letter agreement to be executed by their respective duly authorized persons.

Sincerely,

XENON PHARMACEUTICALS INC.

		
	
 
	
 

	
By:
	
/s/ Robin Sherrington

	
Name:
	
Robin Sherrington

	
Title:
	
EVP, Strategy and Innovation

 

Accepted and agreed:

GENENTECH, INC

		
	
By:
	
/s/ Beth Odeh-Frikert

	
Name:
	
Beth Odeh-Frikert

	
Title:
	
Head Alliance & Asset Management, SSF

F. HOFFMANN-LA ROCHE LTD 

					
	
By:
	
/s/ Franziska Baechler
	
 
	
By:
	
/s/ Melanie Wick

	
Name:
	
Franziska Baechler
	
 
	
Name:
	
Melanie Wick

	
Title:
	
Attorney at Law
	
 
	
Title
	
Authorized SignatoryExhibit 10.1
FORM OF RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE 
DIRECTORS
This Restricted Stock Unit Agreement (this “Agreement”) is made and entered into as of May 18, 2021 (the “Grant Date”) by and between Target Hospitality Corp., a Delaware corporation (the “Company”), and [DIRECTOR NAME] (the “Participant”). This Agreement is being entered into pursuant to the Target Hospitality Corp. 2019 Incentive Award Plan (the “Plan”). Capitalized terms used in this Agreement but not defined herein will have the meaning ascribed to them in the Plan.
1.Grant of Restricted Stock Units. Pursuant to Section 9 of the Plan, the Company hereby issues to the Participant on the Grant Date an Award consisting of [NUMBER] Restricted Stock Units (the “Restricted Stock Units”). Each Restricted Stock Unit represents the right to receive one Common Share, subject to the terms and conditions set forth in this Agreement and the Plan. The Restricted Stock Units shall be credited to a separate account maintained for the Participant on the books and records of the Company (the “Account”). All amounts credited to the Account shall continue for all purposes to be part of the general assets of the Company.
2.Consideration. The grant of the Restricted Stock Units is made in consideration of the services to be rendered by the Participant to the Company.
3.Vesting. Except as otherwise provided herein or in the Plan, provided that the Participant remains in continuous service through the applicable vesting date, the Restricted Stock Units will vest in accordance with the schedule set forth in the chart below (the period during which restrictions apply, the “Restricted Period”). Once vested, the Restricted Stock Units shall become “Vested Units.”
​
	Vesting Date
	    
	Percentage of Vested Units
	    
	Number of Vested Units

	May 18, 2022 or, if earlier, the date of the second Annual Meeting of the Stockholders of the Company following the Grant Date
	​
	100%
	​
	​

​
4.Termination of Service/Change in Control.
4.1The vesting schedule above notwithstanding, if the Participant’s service terminates for any reason at any time before all of the Restricted Stock Units have vested, the Participant’s unvested Restricted Stock Units shall be automatically forfeited upon such termination of service and neither the Company nor any Affiliate shall have any further obligations to the Participant under this Agreement.
4.2Notwithstanding any provision of this Agreement or the Plan to the contrary, upon the occurrence of a Change in Control, any Restricted Period in effect on the date of the Change in Control shall expire as of such date and any unvested Restricted Stock Units shall vest.
​

1

5.Restrictions. Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period and until such time as the Restricted Stock Units are settled, the Restricted Stock Units or the rights relating thereto may not be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by the Participant. Any attempt to assign, alienate, pledge, attach, sell or otherwise transfer or encumber the Restricted Stock Units or the rights relating thereto shall be wholly ineffective and, if any such attempt is made, the Restricted Stock Units will be forfeited by the Participant and all of the Participant’s rights to such units shall immediately terminate without any payment or consideration by the Company. Notwithstanding the foregoing, the Restricted Stock Units may be transferred during the Restricted Period to a Permitted Transferee with the prior written consent of the Committee, in accordance with Section 16(b)(ii) of the Plan. Any Permitted Transferee shall be bound by and subject to all of the terms and conditions of this Agreement and the Plan relating to the transferred Restricted Stock Units except as otherwise provided in Section 16(b)(iii) of the Plan.  The Company shall cooperate with any Permitted Transferee and the Company’s transfer agent in effectuating any transfer permitted under this Agreement.
6.Rights as Shareholder; Dividend Equivalents.
6.1The Participant shall not have any rights of a shareholder with respect to the Common Shares underlying the Restricted Stock Units unless and until the Restricted Stock Units vest and are settled by the issuance of such Common Shares. Upon and following the settlement of the Restricted Stock Units, the Participant shall be the record owner of the Common Shares underlying the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record owner shall be entitled to all rights of a shareholder of the Company (including voting rights).
6.2In the event that the Company pays any cash dividends on its Common Shares between the Grant Date and the date when the Restricted Stock Units are settled in accordance with Section 7 hereof or are forfeited, the Participant’s Account shall be credited on the date such dividend is paid to shareholders with an amount equal to all cash dividends that would have been paid to the Participant if one Common Share had been issued on the Grant Date for each Restricted Stock Unit granted to the Participant (“Dividend Equivalents”). Dividend Equivalents shall be credited to the Participant’s Account and interest may be credited on the amount of cash Dividend Equivalents credited to the Participant’s Account at a rate and subject to such terms as determined by the Committee. Dividend Equivalents credited to the Participant’s Account shall be subject to the same vesting and other restrictions as the Restricted Stock Units to which they are attributable and shall be paid on the same date that the Restricted Stock Units to which they are attributable are settled in accordance with Section 7 hereof. Dividend Equivalents credited to the Participant’s Account shall be distributed in cash or, at the discretion of the Committee, in Common Shares having a Fair Market Value equal to the amount of the Dividend Equivalents and interest, if any. Any accumulated and unpaid Dividend Equivalents attributable to Restricted Stock Units that are cancelled will not be paid and will be immediately forfeited upon cancellation of the Restricted Stock Units.
​

2

7.Payment/Settlement of Restricted Stock Units.
7.1‎Except to the extent the Participant is permitted and makes an election to defer ‎the payment or settlement of the Restricted Stock Units in accordance with Section 7.2 below, ‎promptly upon the expiration of the Restricted Period, and in any event no later than March 15th ‎of the calendar year following the calendar year in which the Restricted Period ends, the ‎Company shall (i) issue and deliver to the Participant, or his or her beneficiary, without charge, the number of Common Shares equal to the number of Vested Units, and (ii) enter the Participant’s name on the books of the Company as the shareholder of record with respect to the Common Shares delivered to the Participant; provided, however, that the Committee may, in its sole discretion elect to (x) pay cash or part cash and part Common Share in lieu of delivering only Common Shares in respect of the Restricted Stock Units, or (y) defer the delivery of Common Shares (or cash or part Common Shares and part cash, as the case may be) beyond the expiration of the Restricted Period if such delivery would result in a violation of applicable law until such time as is no longer the case. If a cash payment is made in lieu of delivering Common Shares, the amount of such payment shall be equal to the Fair Market Value of the Common Shares as of the date on which the Restricted Period lapsed with respect to the Restricted Stock Units, less an amount equal to any required tax withholdings.
7.2‎Notwithstanding the foregoing, the Committee may permit the Participant to ‎make an irrevocable election to defer the delivery of Common Shares (or cash or part Common ‎Shares and part cash, as the case may be) in respect of all or a portion of the Restricted Stock ‎Units to a date or dates beyond the expiration of the Restricted Period, provided that the terms ‎of any such deferral agreement satisfy the requirements of Section 409A of the Code (or any ‎successor) and any regulations or rulings promulgated thereunder (collectively, “Section 409A of ‎the Code”) and any rules and/or procedures adopted by the Committee for the making of such ‎elections.  Any election made by the Participant during the calendar year immediately preceding the year in which this Award is granted shall apply to this Award.  In the event such an election is made and the Participant is a “specified employee” as determined pursuant to Section 409A of the Code, at the time that the Participant receives a payment in connection with the Participant’s “separation from service” as determined pursuant to Section 409A of the Code (other than for death), the payment shall instead be made on the earlier of the first U.S. business day after the date that is (i) six months following the Participant’s separation from service as determined pursuant to Section 409A of the Code, or (ii) the date of the Participant’s death to the extent such delayed payment is otherwise required to avoid a prohibited distribution under Section 409A of the Code.
8.No Rights to Continued Service. Neither the Plan nor this Agreement shall confer upon the Participant any right to be retained in any position, as a director of the Company or any Affiliate or in any other capacity. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company or an Affiliate to terminate the Participant’s service with the Company or an Affiliate at any time.
9.Adjustments. In the event of any change to the outstanding Common Shares or the capital structure of the Company (including, without limitation, a Change in Control), if required, the Restricted Stock Units shall be adjusted or terminated in any manner as contemplated by Section 12 of the Plan.
10.Beneficiary Designation. The Participant may file with the Committee a written designation of one or more persons as the beneficiary(ies) who shall be entitled to his or her rights
​

3

under this Agreement and the Plan, if any, in case of his or her death, in accordance with Section 16(f) of the Plan.
11.Tax Liability and Withholding.
11.1The Participant shall be required to pay, and the Company shall have the right and is authorized to withhold, from any cash, Common Shares, other securities or other property deliverable under this Agreement or from any fees or other amounts owing to the Participant, the amount of any required withholding taxes in respect of the Restricted Stock Units and to take all such other action as the Committee deems necessary to satisfy all obligations for the payment of such withholding taxes in accordance with Section 16(c) of the Plan. The Committee may permit the Participant to satisfy any federal, state or local tax withholding obligation by any of the following means, or by a combination of such means of the Plan, (a) tendering a cash payment, (b) authorizing the Company to withhold Common Shares from the Common Shares otherwise issuable or deliverable to the Participant as a result of the vesting of the Restricted Stock Units (provided, however, that no Common Shares shall be withheld with a value exceeding the maximum amount of tax required to be withheld by law), or (c) delivering to the Company previously owned and unencumbered Common Shares. Notwithstanding the foregoing, in the event the Participant fails to provide timely payment of all sums required to satisfy any applicable federal, state and local withholding obligations in respect of the Restricted Stock Units, the Company shall treat such failure as an election by the Participant to satisfy all or any portion of the Participant’s required payment obligation pursuant to Section 11.1(b) above.
11.2Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding (“Tax-Related Items”), the ultimate liability for all Tax-Related Items is and remains the Participant’s responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting or settlement of the Restricted Stock Units or the subsequent sale of any shares; and (b) does not commit to structure the Restricted Stock Units to reduce or eliminate the Participant’s liability for Tax-Related Items.
12.Compliance with Law. The issuance and transfer of Common Shares shall be subject to compliance by the Company and the Participant with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which the Common Shares may be listed. No Common Shares shall be issued pursuant to Restricted Stock Units unless and until any then applicable requirements of state or federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Participant understands that the Company is under no obligation to register the Common Shares with the Securities and Exchange Commission, any state securities commission or any stock exchange to effect such compliance.
13.Notices. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the General Counsel & Secretary of the Company at the Company’s principal corporate offices. Any notice required to be delivered to the Participant under this Agreement shall be in writing and addressed to the Participant at the Participant’s address as shown in the records of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to time.
​

4

14.Governing Law. This Agreement will be construed and interpreted in accordance with the laws of the State of Texas without regard to conflict of law principles.
15.Interpretation. Any dispute regarding the interpretation of this Agreement shall be submitted by the Participant or the Company to the Committee (excluding the Participant if the Participant serves on the Committee) for review. The resolution of such dispute by the Committee shall be final and binding on the Participant and the Company.
16.Participant Bound by Plan. This Agreement is subject to all terms and conditions of the Plan as approved by the Company’s shareholders. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.
17.Successors and Assigns. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Participant and the Participant’s beneficiaries, executors, administrators and the person(s) to whom the Restricted Stock Units may be transferred by will or the laws of descent or distribution.
18.Severability. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law. If any provision of the Plan or any Award or Award agreement is or becomes or is deemed to be invalid, illegal, or unenforceable in any jurisdiction or as to any person or entity or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision shall be construed or deemed amended to conform to the applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be construed or deemed stricken as to such jurisdiction, person or entity or Award and the remainder of the Plan and any such Award shall remain in full force and effect.
19.Discretionary Nature of Plan. The Plan is discretionary and may be amended, cancelled or terminated by the Company at any time, in its discretion. The grant of the Restricted Stock Units in this Agreement does not create any contractual right or other right to receive any Restricted Stock Units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Participant’s service with the Company.
20.Amendment. The Committee has the right to amend, alter, suspend, discontinue or cancel Restricted Stock Units, prospectively or retroactively; provided that no such amendment shall adversely affect the Participant’s material rights under this Agreement without the Participant’s consent.
​

5

21.Section 409A. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Participant on account of non-compliance with Section 409A of the Code.
22.Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by facsimile transmission, by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.
23.Acceptance. The Participant hereby acknowledges receipt of a copy of the Plan and this Agreement. The Participant has read and understands the terms and provisions thereof, and accepts Restricted Stock Units subject to all of the terms and conditions of the Plan and this Agreement. The Participant acknowledges that there may be adverse tax consequences upon the vesting or settlement of the Restricted Stock Units or disposition of the underlying shares and that the Participant should consult a tax advisor prior to such vesting, settlement or disposition.
[SIGNATURE PAGE FOLLOWS]
​
​

6

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.
​
	​
	TARGET HOSPITALITY CORP.

	​
	​

	​
	​

	​
	By:
	/s/ Heidi D. Lewis

	​
	Name:
	Heidi D. Lewis

	​
	Title:
	EVP, General Counsel & Secretary

	​
	​

	​
	[PARTICIPANT NAME]

	​
	​

	​
	By:
	​

	​
	​
	​

​

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]